Dejgaard TF, von Scholten BJ, Christiansen E, et al. - The effectiveness and glycemic safety of liraglutide in ADJUNCT ONE and TWO did not depend on subgroups, leaving residual beta-cell function as the only identified parameter influencing the effect of glucagon-like peptide-1 receptor agonists (GLP-1 RA) in type 1 diabetes (T1D). Such findings support a role for GLP-1 RAs as adjuncts to insulin in T1D and call for more research.

• ADJUNCT ONE and TWO were randomized controlled phase 3 trials in 1,398 and 835 T1D patients treated with liraglutide (1.8, 1.2 or 0.6 mg) or placebo (adjuncts to insulin), respectively.

• At week 26, the reductions in HbA _1c, body weight, and daily insulin dose did not differ significantly by baseline HbA _1c or BMI in either trial.

• The risk of clinically significant hypoglycemia or hyperglycemia with ketosis was not significantly different depending on baseline HbA _1c, BMI, or insulin regimen.

• These risks did not differ between treatment groups at week 26 in ADJUNCT ONE.

• Placebo-adjusted declines in HbA _1c, body weight, and insulin dose were significant, greater than at week 52, and comparable to those seen in ADJUNCT TWO.